OS Therapies' OST-HER2 Nears FDA Accelerated Approval for Osteosarcoma Amidst ASCO Data Presentation
Decision brief
Answer first · skim in under a minute
OS Therapies is advancing OST-HER2, an immunotherapy for osteosarcoma, towards FDA accelerated approval. The company anticipates presenting crucial survival data at ASCO 2026, aligning with its planned 2026 Biologics License Application (BLA) submission.
OST-HER2, OS Therapies’ Listeria-based HER2-targeted immunotherapy, is advancing through FDA interactions for accelerated approval in recurrent, fully resected pulmonary metastatic osteosarcoma. Phase 2b study NCT04974008 reported statistically significant 12-month event-free survival benefit, while Business Wire updates track rolling BLA plans and Priority Review Voucher eligibility under Rare Pediatric Disease Designation.
Contents9 sections
Key Takeaways
- Phase 2b NCT04974008 enrolled about 39 patients with OST-HER2 maintenance after resection of pulmonary metastatic osteosarcoma.
- Company disclosures cite statistically significant 12-month EFS benefit versus historical controls and ongoing FDA accelerated approval discussions.
- OST-HER2 holds FDA Rare Pediatric Disease, Fast Track and Orphan designations (and EMA orphan/fast-track/ATMP per company releases).
- Accelerated approval still requires a confirmatory trial; PRV eligibility depends on timing of any BLA grant before RPDD program cutoffs.
What does the OST-HER2 Phase 2b trial show?
The Phase 2 study NCT04974008 evaluates OST31-164 (OST-HER2) as osteosarcoma maintenance therapy after resection of pulmonary metastases. ClinicalTrials.gov lists the trial as Phase 2 with about 39 participants and active-not-recruiting status.
Company Business Wire releases state the Phase 2b analysis showed a statistically significant benefit on the 12-month event-free survival primary endpoint. Independent peer-reviewed tables should be used before treating any overall survival percentage as label-ready.
Where does FDA accelerated approval stand for OST-HER2?
OS Therapies has published multiple FDA meeting updates on Business Wire, including positive feedback on an accelerated approval pathway and End-of-Phase 2 / pre-BLA sequencing for prevention or delay of recurrence after complete resection of pulmonary metastatic osteosarcoma.
See June 2025 Business Wire FDA feedback and EOP2 meeting notice. Rolling review, if granted, lets modules submit asynchronously but does not guarantee approval.
Why do Rare Pediatric Disease designations matter commercially?
Company releases state OST-HER2 has Rare Pediatric Disease Designation. If a BLA is granted under qualifying conditions, the sponsor may become eligible for a Priority Review Voucher. Historical PRV sale prices fluctuate; they should not be booked as certain cash.
FDA’s accelerated approval framework still expects confirmatory evidence. Sponsors must start or commit to a randomized confirmatory study as part of the pathway. Review general accelerated approval principles on FDA’s Accelerated Approval Program page.
For BD teams, the commercial case mixes a rare pediatric oncology niche with potential PRV monetization and limited competition after decades without new osteosarcoma standards. Manufacturing scale for a live Listeria vector and pediatric site activation for confirmatory work remain the operational bottlenecks after any accelerated approval.
What remains unproven for OST-HER2?
“Nears approval” language overstates status until FDA issues an approval letter. Historical-control EFS comparisons face scrutiny. Manufacturing comparability for a Listeria vector, pediatric dosing and EU conditional marketing timelines are separate workstreams from U.S. accelerated approval.
How should ASCO and congress data be weighted?
Congress abstracts and company slides can update survival curves after the primary EFS analysis. Treat each cut as incremental, not as a new primary endpoint unless the statistical analysis plan says so. Historical-control comparisons remain the central methodological debate for accelerated approval in resected metastatic osteosarcoma.
Sponsors and KOLs will argue that decades without new options justify flexibility. FDA reviewers will ask whether the control benchmark is contemporaneous and whether selection bias inflated event-free survival. Confirmatory randomization is the expected price of accelerated approval.
Commercial teams modeling Priority Review Voucher cash should haircut probability-weighted proceeds. Voucher markets move with legislative sunsets and buyer demand. A rolling BLA improves interaction cadence but does not shorten the clinical evidence bar.
Until an approval letter posts, OST-HER2 remains investigational. Site staff should continue to manage patients under trial or expanded-access frameworks rather than assuming near-term label availability in 2026.
Related NovaPharma coverage
- OS Therapies OST-HER2 Phase 2b results
- OST-HER2 EMA conditional path coverage
- Ivonescimab HARMONi-6 coverage
Pediatric oncology networks will also weigh travel burden, Listeria shedding precautions and long-term immune monitoring when considering confirmatory trial participation. Those practical issues shape enrollment velocity as much as statistical power calculations do. Companies that under-resource site support often miss accelerated approval calendars even after constructive FDA meetings.
Frequently Asked Questions
What trial supports OST-HER2 in metastatic osteosarcoma?
Phase 2 study NCT04974008 evaluates OST-HER2 (OST31-164) as maintenance therapy after resection of pulmonary metastatic osteosarcoma, with about 39 enrolled participants.
Is OST-HER2 FDA-approved?
Not yet. OS Therapies has disclosed FDA meetings supporting an accelerated approval strategy and rolling BLA plans, but approval requires a completed review and agency decision.
What designations has OST-HER2 received?
Company Business Wire releases state FDA Rare Pediatric Disease, Fast Track and Orphan designations, with EMA orphan, Fast Track and ATMP designations also cited by the sponsor.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for OST-HER2.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
